Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial
Neuropsychopharmacology Reports · 2024-06 · 44 (2) · 389-398
DOI: 10.1002/npr2.12431 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 10.04.2024. Verfasst von Aida Mohammadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Schizophrenia, Probiotics, Vitamin D, Cognition. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
Manipulation of the intestinal microbiome and supplying vitamin D can attenuate psychiatric symptoms in schizophrenic patients. The current study tried to evaluate the effects of probiotic/vitamin D supplementation on the cognitive function and disease severity of schizophrenic patients.
Methods
In the present study, 70 patients (aged 18–65) with schizophrenia were recruited. Participants were randomly allocated to the placebo ( n = 35) and intervention (probiotic supplements+400 IU vitamin D, n = 35) groups. Severity of disease and cognitive function (primary outcomes) were evaluated by Positive and Negative Syndrome Scale (PANSS) and Montreal Cognitive Assessment (MoCA) tests, respectively. Moreover, lipid profile, body mass index (BMI), gastrointestinal (GI) problems, serum C‐reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated as secondary outcomes.
Results
A total of 69 patients completed the study. The MoCA score was increased by 1.96 units in the probiotic‐containing supplement group compared to the placebo ( p = 0.004). Also, the percentage of subjects with MoCA score ≥ 26 rose significantly in the intervention group ( p = 0.031). Moreover, TC ( p = 0.011), FBS ( p = 0.009), and CRP ( p < 0.001) significantly decreased in the supplement group compared to the placebo. Although the probiotic supplement reduced PANSS score by 2.82 units, the difference between the study groups was not statistically significant ( p = 0.247).
Conclusion
Co‐administration of probiotics and vitamin D has beneficial effects on the improvement of cognitive function in schizophrenic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
- Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
- Department of Biology, Tehran Central Branch, Islamic Azad University, Tehran, Iran.
ORCID-Profile: Aida Mohammadi, Gita Sadighi, Ali Nazeri Astaneh, Maryam Tajabadi-Ebrahimi, Tahereh Dejam
Zitieren
APA
Mohammadi, A., Sadighi, G., Nazeri Astaneh, A., Tajabadi-Ebrahimi, M., & Dejam, T. (2024). Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial. Neuropsychopharmacology Reports, 44(2), 389-398. https://doi.org/10.1002/npr2.12431
Vancouver
Mohammadi A, Sadighi G, Nazeri Astaneh A, Tajabadi-Ebrahimi M, Dejam T. Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial. Neuropsychopharmacology Reports. 2024;44(2):389-398. doi:10.1002/npr2.12431
BibTeX
@article{Mohammadi2024,
author = {Mohammadi, Aida and Sadighi, Gita and Nazeri Astaneh, Ali and Tajabadi-Ebrahimi, Maryam and Dejam, Tahereh},
title = {Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial},
journal = {Neuropsychopharmacology Reports},
year = {2024},
volume = {44},
number = {2},
pages = {389--398},
doi = {10.1002/npr2.12431}
}
EUVIMED